peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Potash is primarily a mixture of potassium salts because plants have little or no sodium content, and the rest of a plant's major mineral content consists of calcium salts of relatively low solubility in water. While potash has been used since ancient times, its composition was not understood. Georg Ernst Stahl obtained experimental evidence that led him to suggest the fundamental difference of sodium and potassium salts in 1702, and Henri Louis Duhamel du Monceau was able to prove this difference in 1736. The exact chemical composition of potassium and sodium compounds, and the status as chemical element of potassium and sodium, was not known then, and thus Antoine Lavoisier did not include the alkali in his list of chemical elements in 1789. For a long time the only significant applications for potash were the production of glass, bleach, soap and gunpowder as potassium nitrate. Potassium soaps from animal fats and vegetable oils were especially prized because they tend to be more water-soluble and of softer texture, and are therefore known as soft soaps. The discovery by Justus Liebig in 1840 that potassium is a necessary element for plants and that most types of soil lack potassium caused a steep rise in demand for potassium salts. Wood-ash from fir trees was initially used as a potassium salt source for fertilizer, but, with the discovery in 1868 of mineral deposits containing potassium chloride near Staßfurt, Germany, the production of potassium-containing fertilizers began at an industrial scale.
== Research contributions == Kahn is an investigator in insulin signal transduction and mechanisms of altered signaling in diabetes. The main discoveries to come from his lab include the insulin receptor kinase, its two primary substrates and the molecular components of the insulin signaling network. Kahn's lab was also the first to define alterations in the signaling network in insulin resistant states, such as type 2 diabetes. More recent discoveries from his lab encompass defining alterations in the signaling network in type 2 diabetes, including the important role of insulin action in unexpected tissues such as brain, both in physiologic regulation and potentially in development of Alzheimer's disease. His lab at Joslin has also made contributions to the understanding of obesity by showing that fat cells, called adipocytes, have different developmental origins and cellular functions that lead to risk of metabolic disease. Kahn's work with adult humans has demonstrated that they have active brown fat that is central to redefining its role in metabolic regulation and protection from obesity.
There are many cultivars of blackcurrant. 'Baldwin' was the mainstay of the industry for many years but it has now largely been superseded by more productive and disease-resistant varieties. During the 20th century in Europe, much hybridisation work has been carried out in order to reduce the plant's susceptibility to disease and frost and also to increase yields. This effort centered mainly in Scotland, Poland, and New Zealand. In Britain the Scottish Crop Research Institute was tasked with developing new varieties suitable for growing in the north of the country. They produced new cultivars that had greater cold tolerance, especially in the spring, ripened earlier and more evenly and had greater fungal disease resistance. Frost tolerance was improved by selecting for late flowering and genetic research identified genes involved in resistance to gall mite and the blackcurrant reversion virus. 'Ben Lomond' was the first of the 'Ben' varieties and was released in 1975. This was followed by several other cultivars for the juicing industry such as 'Ben Alder' and 'Ben Tirran'. The cultivar 'Ben Hope' was released in 1998 with increased tolerance to gall mite, and in the same year, 'Ben Gairn' became available. It shows resistance to the reversion virus. For gardeners and the pick-your-own market, 'Ben Sarek', 'Ben Connan' and 'Big Ben' were introduced and have large, sweet berries. The cultivars 'Ben Connan' and 'Big Ben' have gained the Royal Horticultural Society's Award of Garden Merit.
Sources: en.wikipedia.org
As the confinement energy depends on the quantum dot's size, both absorption onset and fluorescence emission can be tuned by changing the size of the quantum dot during its synthesis. The larger the dot, the redder (lower-energy) its absorption onset and fluorescence spectrum. Conversely, smaller dots absorb and emit bluer (higher-energy) light. Recent articles suggest that the shape of the quantum dot may be a factor in the coloration as well, but as yet not enough information is available . Furthermore, it was shown that the lifetime of fluorescence is determined by the size of the quantum dot. Larger dots have more closely spaced energy levels in which the electron–hole pair can be trapped. Therefore, electron–hole pairs in larger dots live longer causing larger dots to show a longer lifetime. To improve fluorescence quantum yield, quantum dots can be made with shells of a larger bandgap semiconductor material around them. The improvement is suggested to be due to the reduced access of electron and hole to non-radiative surface recombination pathways in some cases, but also due to reduced Auger recombination in others.
=== Afonso Dias === In one of the Dias' hearings, it was brought up that the defendant came from a poor family, was 22 and played with an 11 year old child at the time of the disappearance. It was also brought up that the defendant was meeting up with Mendonça in private as Mendonça's parents had forbidden it, after Dias came back changed from the army and as a deserter. Manuel Mendonça said that he and the neighbors noticed that Dias' financial resources increased after the boy's disappearance and that the first PJ team did not believe the information received from both the prostitute and the family. Dias was an unhygienic person, however in the day of the disappearance he took two baths. When Manuel Mendonça got to the PJ they said it was not possible to extract anything from the suspect's clothes. Manuel Mendonça also said that Dias laughed while talking to Filomena Teixeira. He also said that the defendant's lawyer and family did not want to help to find Mendonça. The chief-inspector Henrique Noronha said in 2011 that in the reconstitution there was "a hiatus of time that we couldn't figure out (...) We were a bit perplexed [when Afonso Dias said that he] stood in a place looking at nothing and burning the midnight". The inspector also said that he did not understand the reason of not following the lead of Alcina Dias. Hélder Silva, that was one of the five children that saw Mendonça for the last time, told the Correio da Manhã that Dias "Was very weird. Afonso knew Rui Pedro's whole life, where he was, who he was with, what he would do the next day.
=== 2008 === While running at training after round Four in 2008, Davey twisted and injured his right knee when changing direction, requiring immediate surgery and making him unavailable for the rest of the season because this would require him to miss between 6 and 12 months. Despite the injury, Davey continued to train but coach Matthew Knights did not risk him.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.